SELLAS Life Sciences Group, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLS research report →
Companywww.sellaslifesciences.com
SELLAS Life Sciences Group, Inc. , a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
- CEO
- Angelos Stergiou
- IPO
- 2008
- Employees
- 15
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $1.28B
- P/E
- -52.52
- P/S
- 0.00
- P/B
- 14.40
- EV/EBITDA
- -49.18
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -47.12%
- ROIC
- -29.06%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-26,863,000 · 13.01%
- EPS
- $-0.25 · 50.00%
- Op Income
- $-28,274,000
- FCF YoY
- 19.81%
Performance & Tape
- 52W High
- $9.10
- 52W Low
- $1.39
- 50D MA
- $5.13
- 200D MA
- $3.22
- Beta
- 2.24
- Avg Volume
- 7.02M
Get TickerSpark's AI analysis on SLS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 7, 26 | Varian John | other | 50,000 |
| Jan 7, 26 | VAN NOSTRAND ROBERT L | other | 50,000 |
| Jan 7, 26 | SCHEINBERG DAVID A | other | 50,000 |
| Jan 7, 26 | CICIC DRAGAN | other | 300,000 |
| Jan 7, 26 | Burns John Thomas | other | 300,000 |
| Jan 7, 26 | Kalin Katherine Bach | other | 50,000 |
| Jan 7, 26 | Wasman Jane | other | 50,000 |
| Dec 3, 25 | CICIC DRAGAN | other | 63,800 |
| Dec 3, 25 | Burns John Thomas | other | 58,592 |
| Dec 3, 25 | Stergiou Angelos M. | other | 187,066 |
Our SLS Coverage
We haven't published any research on SLS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SLS Report →